-
Klotho Neurosciences expands beyond neurology into longevity research
-
Klotho Neurosciences partners with AAVnerGene for gene therapy manufacturing
-
Klotho Neurosciences regains compliance with NASDAQ listing rules
-
Klotho Neurosciences receives FDA orphan drug designation for ALS treatment
-
Klotho Neurosciences (KLTO) Files $100M Mixed Shelf
-
Klotho Neurosciences (KLTO) Announces Mutual Termination Of Share Exchange Agreement With Skybell Technologies (Skybell), To Continue Its Focus On Therapeutics And Longevity Programs
-
Klotho Neurosciences (KLTO) Raises Over $11 Million, Retires All Debt, And Exceeds Nasdaq Stockholders' Equity Requirement
-
Klotho Neurosciences (KLTO) Appoints Peter Moriarty as COO
-
Klotho Neurosciences (KLTO) Appoints Robert Langer to its Board
-
ANEW MEDICAL (WENA) to Rebrand as Klotho Neurosciences (KLTO)

